Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 34,668 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 34,668 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.60, for a total transaction of $644,824.80. Following the completion of the sale, the insider directly owned 1,187,644 shares in the company, valued at approximately $22,090,178.40. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Adaptive Biotechnologies Trading Down 6.5%

Shares of NASDAQ ADPT traded down $1.20 during trading on Wednesday, reaching $17.30. 2,165,376 shares of the company traded hands, compared to its average volume of 1,785,883. The stock has a market cap of $2.64 billion, a P/E ratio of -32.04 and a beta of 2.18. The firm’s fifty day simple moving average is $17.17 and its 200 day simple moving average is $15.15. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company’s revenue was up 102.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) earnings per share. As a group, research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. boosted its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares during the last quarter. Jennison Associates LLC lifted its holdings in Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after purchasing an additional 1,363,181 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in Adaptive Biotechnologies during the 3rd quarter worth $14,934,000. Finally, First Trust Advisors LP grew its holdings in shares of Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock worth $8,636,000 after buying an additional 726,184 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ADPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday. Piper Sandler increased their target price on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Finally, BTIG Research raised their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $17.22.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.